Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History JAZZ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics JAZZ

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Jazz Pharmaceuticals PLC

JAZZ
Current price
106.76 USD -0.61 USD (-0.57%)
Last closed 107.51 USD
ISIN USG508711052
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 6 549 710 336 USD
Yield for 12 month -2.80 %
1Y
3Y
5Y
10Y
15Y
JAZZ
21.11.2021 - 28.11.2021

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland. Address: Waterloo Exchange, Dublin, Ireland, D04 E5W7

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

188.63 USD

P/E ratio

14.71

Dividend Yield

Financials JAZZ

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures JAZZ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+4 068 950 000 USD

Last Year

+3 834 204 000 USD

Current Quarter

+897 841 000 USD

Last Quarter

+1 088 173 000 USD

Current Year

+3 623 237 000 USD

Last Year

+3 398 627 000 USD

Current Quarter

+793 221 000 USD

Last Quarter

+959 460 000 USD
EBITDA 1 392 039 040 USD
Operating Margin TTM -2.90 %
Price to Earnings 14.71
Return On Assets TTM 3.99 %
PEG Ratio 3.93
Return On Equity TTM 12.25 %
Wall Street Target Price 188.63 USD
Revenue TTM 4 064 807 936 USD
Book Value 67.75 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -0.50 %
Dividend Yield
Gross Profit TTM 3 745 913 088 USD
Earnings per share 7.36 USD
Diluted Eps TTM 7.36 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY 118.50 %
Profit Margin 11.86 %

Stock Valuation JAZZ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 14.71
Forward PE 12.18
Enterprise Value Revenue 2.29
Price Sales TTM 1.61
Enterprise Value EBITDA 7.46
Price Book MRQ 1.55

Technical indicators JAZZ

For 52 weeks

95.49 USD 148.06 USD
50 Day MA 107.91 USD
Shares Short Prior Month 5 951 696
200 Day MA 118.25 USD
Short Ratio 4.27
Shares Short 5 714 162
Short Percent 10.92 %